Atherosclerosis: aspirin may be useful among patients with a prior ischaemic event

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In outpatients with stable atherosclerosis, aspirin use was marginally beneficial only among patients with atherosclerosis with a prior ischaemic event.

Why this matters

  • Although not well studied, aspirin has been assumed to be of benefit and recommended in all forms of atherosclerosis, including those without a prior ischaemic event.

Study design

  • Participants from the Reduction of Atherothrombosis for Continued Health (REACH) registry were followed prospectively for up to 4 y.
  • Patients were divided according to prior ischaemic event (n=21,724) vs stable atherosclerosis, but no prior ischaemic event (n=11,872).
  • Primary outcome was the first occurrence of cardiovascular death, myocardial infarction (MI) or stroke.
  • Funding: None disclosed.

Key result...